Azacitidine

CHEMBL1489 Phase 4 承認済み Small molecule

Half-Life

—

Bioavailability

—

Protein Binding

—

Molecular Weight

244.2 g/mol

LogP

-2.2

Phase

4

A hypomethylating agent that incorporates into DNA and inhibits DNA methyltransferase, reactivating silenced tumor suppressor genes in abnormal blood cells. It is used in myelodysplastic syndromes and acute myeloid leukemia to slow disease progression.

分子量

244.2000 g/mol

LogP

-2.20

TPSA

141.00 Å²

リピンスキーの五則

適合

治療領域

Ovarian Cancer Pancreatic Cancer Bladder Cancer Thyroid Cancer Endometriosis Benign Prostatic Hyperplasia Glaucoma Cardiovascular Disease Age-Related Macular Degeneration Neurology Psychiatry Endocrinology Respiratory Disease Dermatology Hematology Pain Management Ophthalmology Non-Small Cell Lung Cancer Rheumatoid Arthritis Osteoporosis Asthma Chronic Obstructive Pulmonary Disease Immunology Alzheimer's Disease Parkinson's Disease Epilepsy Migraine Schizophrenia Bipolar Disorder Generalized Anxiety Disorder Insomnia Infectious Disease Melanoma Hepatology Oncology Nephrology Gastroesophageal Reflux Disease Inflammatory Bowel Disease Psoriasis Obstetrics & Gynecology Anesthesiology Systemic Lupus Erythematosus Multiple Sclerosis Chronic Kidney Disease Non-Alcoholic Fatty Liver Disease Urology Stroke Deep Vein Thrombosis / Pulmonary Embolism Hyperlipidemia Obesity Lymphoma Gastroenterology Rheumatology Transplant Medicine Type 2 Diabetes Hypertension Major Depressive Disorder Breast Cancer Atopic Dermatitis Gout Chronic Pain Malaria HIV/AIDS Hepatitis C Tuberculosis Heart Failure Atrial Fibrillation Prostate Cancer Colorectal Cancer Leukemia

Pharmacokinetics (PK)

Pharmacodynamics (PD)

2D構造

SVG PNG

Cite this structure

Embed this structure

SMILES

Nc1ncn([C@@H]2O[C@H](CO)[C@@H](O)[C@H]2O)c(=O)n1

InChI

InChI=1S/C8H12N4O5/c9-7-10-2-12(8(16)11-7)6-5(15)4(14)3(1-13)17-6/h2-6,13-15H,1H2,(H2,9,11,16)/t3-,4-,5-,6-/m1/s1

Molecular Formula

C8H12N4O5

HBD / HBA

4 / 5

回転可能結合数

2

重原子数

17

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

よくある質問

A hypomethylating agent that incorporates into DNA and inhibits DNA methyltransferase, reactivating silenced tumor suppressor genes in abnormal blood cells. It is used in myelodysplastic syndromes and acute myeloid leukemia to slow disease progression.

Yes, Azacitidine is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1489. Open-access bioactivity database.
PubChem — National Center for Biotechnology Information (NCBI). CID 9444. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.

PillFYI

患者向けのわかりやすい情報をお探しですか？

Azacitidine PillFYIで

構造

クイックデータ

分子式: C8H12N4O5
同義語: 3

外部リンク

Cite

BibTeX, APA, MLA, Chicago, IEEE, Harvard

医学的免責事項

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.